Literature DB >> 20575599

A retrospective study on a cohort of patients with lymphocytic colitis.

D Simondi1, R Pellicano, S Reggiani, F Pallavicino, E David, C Sguazzini, A G Bonagura, A La Terra, M Rizzetto, M Astegiano.   

Abstract

OBJECTIVE: The term "microscopic colitis" includes lymphocytic colitis (LC) and collagenous colitis, bearing common clinical presentation distinguishable only by histopathological examination of colonic biopsies. This study reports on demographic and clinical characteristics, and outcome of a cohort of patients with LC.
METHODS: Demographic, clinical and histopathological data were reviewed. Every patient underwent total colonoscopy with multiple biopsies examined by an expert pathologist. Diagnosis of LC was confirmed if histopathological criteria were present. Routine laboratory tests were collected to rule out other diagnosis.
RESULTS: We included 80 patients (28 males; mean age: 46.4 years). At diagnosis, 71 patients (88%) reported diarrhea, 46 (58%) abdominal pain, 21 (36%) weight loss, 10 (13%) nausea. Regarding autoimmune or inflammatory diseases accompanying LC, thyroid disorders and celiac disease (CD) ranked first. Moreover, in over 10% of patients who underwent esophagogastroduodenoscopy, duodenal biopsies showed villi alterations classified as Marsh I damage, without clinical and serological data for diagnosis of CD. Mesalazine and oral topical steroids (budesonide or beclomethasone) were used to treat LC in 34 (43%) and 32 (39%) of patients, respectively, with similar percentages of clinical response (approximately 80%).
CONCLUSIONS: The need for total colonoscopy with multiple biopsies in all patients with chronic watery diarrhea was confirmed. Since the association between CD and LC exists, additional tests should be performed in patients not responding to gluten-free diet or to LC specific therapy to exclude the other condition. Mesalazine obtained a similar outcome than oral steroids in this cohort.

Entities:  

Mesh:

Year:  2010        PMID: 20575599     DOI: 10.4321/s1130-01082010000600007

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  6 in total

1.  Beclomethasone dipropionate in microscopic colitis: Results of an exploratory open-label multicentre study (COLCO).

Authors:  Thomas De Corte; Emilie Janssens; Ann D'Hondt; Koen Thorrez; Joris Arts; Katrien Dejaegher; François D'Heygere; Annelies Holvoet; Bart van Besien; Luc Harlet; Harald Peeters; Wouter Van Moerkercke; Filip Baert
Journal:  United European Gastroenterol J       Date:  2019-07-12       Impact factor: 4.623

2.  Successful use of beclometasone dipropionate for the treatment of microscopic colitis.

Authors:  Ian Lp Beales
Journal:  United European Gastroenterol J       Date:  2020-05-23       Impact factor: 4.623

Review 3.  Celiac Disease Is Associated with Microscopic Colitis in Refractory Cases in Adults: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Muhammad Aziz; Hossein Haghbin; Raja Samir Khan; Zubair Khan; Simcha Weissman; Faisal Kamal; Wade Lee-Smith; Saurabh Chandan; Joseph D Feuerstein; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2021-08-27       Impact factor: 3.487

4.  The association between microscopic colitis and celiac disease: a systematic review and meta-analysis.

Authors:  Faisal M Nimri; Adel Muhanna; Zain Almomani; Shrouq Khazaaleh; Mohammad Alomari; Laith Almomani; Alisa Likhitsup
Journal:  Ann Gastroenterol       Date:  2022-04-08

5.  Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.

Authors:  Cosimo Prantera; Stefano Marconi
Journal:  Therap Adv Gastroenterol       Date:  2013-03       Impact factor: 4.409

Review 6.  Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Francesco Manguso; Raffaele Bennato; Giovanni Lombardi; Elisabetta Riccio; Giuseppe Costantino; Walter Fries
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.